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Axitinib is a potent, selective, vascular endothelial growth factor receptor inhibitor with demonstrated
efficacy as second-line treatment for metastatic renal cell carcinoma. Analyses of axitinib drug exposures
have demonstrated high interpatient variability in patients receiving the 5 mg twice-daily (b.i.d.) starting
dose. Clinical criteria can be used to assess whether individual patients may benefit further from dose
modifications, based on their safety and tolerability data. This review provides practical guidance on the
‘flexible dosing’ method, to help physicians identify who would benefit from dose escalations, dose re-
ductions or continuation with manageable toxicity at the 5 mg b.i.d. dose. This flexible approach allows
patients to achieve the best possible outcomes without compromising safety.
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Rationale for individualized dosing
Before the development of molecular targeted therapy, most available anticancer drugs, with hormone therapies
and immunotherapies being notable exceptions, were chemotherapy agents: chemicals aimed at having a cytotoxic
effect on cancer cells [1,2]. These drugs were dosed according to a patient’s weight or body surface area, based on
the observation that patients with a greater body size generally have a greater volume of distribution and require
higher doses than smaller patients to reach equal drug concentrations [3]. It was thought this approach would deliver
consistent systemic drug exposure, thereby optimizing treatment outcomes. This dosing approach was also chosen
based on a lack of a better option at that time. However, it was known that multiple factors beyond patient size
(including age, sex, renal function, hepatic function, concomitant medication, disease state and genetics) could
have an impact on the actual concentration of a drug in an individual’s bloodstream [4]. Consequently, there remains
high variability between patients (interpatient variability) in systemic drug concentrations, even when normalized
for weight/body surface area [5].
When molecular targeted agents were first introduced for use in metastatic renal cell carcinoma (mRCC), these
drugs were recommended at a fixed dose, based on an assumption that the maximum tolerated fixed dose would
result in the best efficacy and that this same high dose would be appropriate for all patients. However, most
tyrosine kinase inhibitors (TKIs) demonstrate high interpatient variability in drug exposure (depending on oral
bioavailability and first-pass liver metabolism of drugs); therefore, the subsequent therapeutic effect and toxicity
for the same administered dose may vary [6]. As a result, fixed dosing may result in suboptimal efficacy for some
patients or excessive toxicity in others [7]. In addition, higher-than-needed doses may be excessive if therapeutic
effects are already achieved at lower doses.
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Table 1. The half-life, starting dose and schedule of oral targeted metastatic renal cell carcinoma drugs.
Drug name Half-life (h) Starting dose Schedule
Sunitinib 40–60 (80–110 [active metabolite]) 50 mg Once-daily dosing
Pazopanib 30.9 800 mg Once-daily dosing
Sorafenib 25–48 400 mg Twice-daily dosing†
Everolimus 30 10 mg Once-daily dosing
Cabozantinib ∼99 60 mg Once-daily dosing
Lenvatinib ∼28 18 mg Once-daily dosing‡
Axitinib 2.5–6.1 5 mg Twice-daily dosing
Data taken from [13–19].
†Sorafenib is dosed twice-daily, despite having a half-life ranging from 25 to 48 h. This is because of its low bioavailability.
‡ In combination with everolimus 5 mg once-daily. The daily doses of lenvatinib and, if necessary, everolimus are to be modified as needed according to the dose/toxicity management
plan.
It is therefore apparent that neither the weight/body surface area-based approach nor the fixed-dosing approach
is sufficient to account for interpatient variability, and a more flexible, individualized method (to find the optimal
dose for an individual patient) should be employed in some therapeutic scenarios [5,8]. If not, there is a risk that the
patient will have suboptimal treatment outcomes due to either excessive toxicity or inadequate drug exposure [9].
Given the noncurative nature of these agents, it is important that a balance is reached to allow us to carefully
optimize efficacy while managing adverse effects.
Axitinib is a potent, selective, second-generation VEGFR inhibitor with demonstrated efficacy as second-line
treatment for mRCC [9,10]. Analyses of drug exposures in patients receiving the 5 mg twice-daily (b.i.d.) starting
dose of axitinib have demonstrated high interpatient variability [8].
This review explores how the properties of axitinib contribute to its dosing profile and provides the rationale for
why a flexible dosing method, based on individual safety and tolerability, gives us the opportunity to account for
interpatient variability. Practical clinical guidance is also offered to help physicians individualize the axitinib dose
and achieve the best possible outcomes for every patient.
How the dosing schedule & starting dose of axitinib were determined
All drugs have different properties, resulting in different doses and schedules that are determined during the clinical
development program for each drug (Table 1). The half-life of a drug (defined as the time taken for the plasma
drug concentration to reduce from peak concentration by half ) is a key factor that helps inform how often a drug
needs to be dosed [11,12]. As repeated doses are administered, the plasma concentration will usually build up and
reach steady state, a concentration level that should be in the therapeutic range, for as long as regular doses are
administered to balance the amount of drug being cleared [11]. The plasma half-life of axitinib ranges from 2.5 to
6.1 h; steady state is expected within 2–3 days of the initial dose and is maintained by b.i.d. dosing. B.i.d. dosing
allows the therapeutic levels of axitinib to be maintained constantly when taken approximately 12 h apart [13].
As such, it is not necessary to administer axitinib more than twice daily. However, owing to the short half-life
of axitinib, it is not appropriate to alter the schedule to once-daily; doing this would compromise the efficacy of
axitinib because plasma concentrations would fall below therapeutic levels.
The maximum tolerated dose – that is, the dose immediately below that which causes dose-limiting toxicity
according to a predefined threshold – was determined for axitinib in a Phase I trial of patients with various advanced
solid malignancies [20]. 36 patients received fixed doses (5–30 mg b.i.d.) of axitinib in 28-day cycles; the maximum
tolerated dose and recommended dose to be taken into Phase II and III trials was 5 mg b.i.d. The tolerability of
this dose was confirmed in a large Phase III study (AXIS), in which the 5 mg b.i.d. starting dose was used [10].
Although the appropriate starting dose of axitinib is 5 mg b.i.d., this nonindividualized fixed dose does not take
into account interpatient variability. Therefore, it is important that after initiation at 5 mg b.i.d., clinical criteria
are used to guide whether the patient would benefit from a dose adjustment; these criteria are described in a later
section of this review. First, however, it is important to understand why interpatient variability exists and why we
need to account for it.
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Figure 1. Factors that can lead to interpatient variability in drug exposure.
ADME: Absorption, distribution, metabolism, elimination.
Reproduced with permission from [22] C© Elsevier (2015).
Interpatient variability in axitinib exposure
Factors affecting drug exposure
A number of factors and metabolic processes in the body affect drug exposure. As can be expected, these factors are
not the same in every patient, and there can also be differences in the impact of metabolic processes on exposure
in an individual patient (Figure 1) [21,22]. For example, absorption, distribution, metabolism and elimination
(ADME) all influence drug exposure [4]. After oral administration, axitinib shows a variable rate of absorption,
reaching peak concentrations in plasma within 4 h [13,23]. Results from in vitro studies have demonstrated that
axitinib is highly protein bound (>99%), mostly to albumin, with moderate binding to α1-acid glycoprotein [13,24].
Metabolism of axitinib is primarily performed by CYP3A4/5 in the liver and, to a lesser extent, by CYP1A2,
CYP2C19 and UDP glucuronosyltransferase 1 family polypeptide A1 (UGT1A1) [13,24]. The main metabolites of
axitinib are inactive [20,24]. Approximately 30–60% of orally administered axitinib is eliminated in the feces, with
a further 23% eliminated renally [13]. Variability between patients in each of the four ADME processes has a direct
impact on drug exposure and helps to explain why giving a fixed standard dose of a drug to all patients will not
always produce either the same anticancer effect or the same side effects [7,21]. In addition, most drug-metabolizing
enzymes are polymorphic; therefore, a patient’s response to treatment can be affected by genetic variation [21].
Other factors affecting drug exposure include interactions with co-administered drugs that can lead to variation
in plasma concentrations; the importance of drug–drug interactions on the safety profile of axitinib should be
evaluated on an individual basis and physicians should be aware of the most common drug–drug interactions
(Supplementary Table 1) [25]. Co-administration of axitinib with agents known to be strong CYP3A4/5 inhibitors
(e.g., ketoconazole and clarithromycin) or inducers (e.g., phenytoin, dexamethasone, rifampicin and St John’s wort)
may cause axitinib plasma concentrations to increase or decrease, respectively [26].
Furthermore, for self-administered, oral regimens, compliance is an essential factor in determining efficacy. If
a patient has poor compliance, this can impact on drug exposure and can be another factor that contributes
to variability [27]. Notably, nearly all patients receiving axitinib for renal cancer will have previously received an
alternative TKI – most likely according to a once-daily and (in the case of sunitinib) intermittent dosing schedule.
Therefore, it is essential that patients clearly understand the dosing schedule for axitinib before commencing this
treatment.
Variability in exposure in patients given a standard dose of axitinib 5 mg b.i.d.
In a retrospective analysis of pooled data [8] (two Phase II studies in which axitinib was evaluated in cytokine-
refractory mRCC [n = 116] [28,29] and one Phase II study in which axitinib was evaluated in sorafenib-refractory
mRCC [n = 62] [30]), variability in axitinib exposure (as measured by the area under the plasma concentration–
time curve [AUC]) was demonstrated in patients after they each received the same standard dose of 5 mg b.i.d.;
Figure 2A shows the extent to which variations occurred between patients. Variations in axitinib exposure (expressed
as coefficient of variation of up to 94%) have been previously reported; this variability in exposure is not unique to
axitinib and similar variations can also be demonstrated with all other oral mRCC drugs [21,22].
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Figure 2. Variability in exposure (as measured by area under the plasma concentration–time curve) in patients given a standard dose of
axitinib 5 mg b.i.d. Individual patients’ exposure levels: (A) all patients; (B) patients who remained on axitinib 5 mg b.i.d.; (C) before and
after dose escalation to axitinib 7 mg b.i.d.; (D) before and after dose escalation to axitinib 10 mg b.i.d. (E) Median axitinib exposure
levels in (B) to (D). (F) Patients who can achieve a higher axitinib exposure have a better clinical outcome [8]. The central boxes represent
the values ranging from the lower to the upper quartile (25th–75th percentile); the middle line of each box represents the median. Each
dot represents an individual patient’s exposure level.
†Exposure (as measured by AUC) at the end of 4 weeks of study treatment.
‡Three enrolled patients were not included in the analysis because of lack of dose-time data or only one measurable axitinib
concentration [30].
§36 patients met the AUC criterion; 26 PFS events were assessed by the investigator.
¶139 patients met the AUC criterion; 83 PFS events were assessed by the investigator.
AUC: Area under the plasma concentration–time curve; AUC12: Area under the plasma concentration–time curve from 0 to 12 h; b.i.d.:
Twice-daily; Cl: Confidence interval; HR: Hazard ratio; PFS: Progression-free survival; RCC: Renal cell carcinoma.
Because of the interpatient variability in half-life and exposure seen with axitinib, it is not possible to predict the
exact exposure level a patient will have. However, Rini et al. demonstrated that increasing the axitinib dose leads to
increased exposure [9]. Patients who, based on tolerability criteria, were eligible for subsequent dose escalation up to
7 mg b.i.d. (Figure 2C) and then 10 mg b.i.d. (Figure 2D) had lower median axitinib exposure to begin with at 5 mg
b.i.d. than patients who were not eligible for dose escalation (Figure 2B). After dose escalation, median axitinib
exposure increased to similar levels as those for patients who were not eligible for dose escalation (Figure 2E). These
pharmacokinetic (PK) data confirm that exposure can be increased (via a dose escalation) in patients who are able
to tolerate it.
Interpatient variability in drug exposure translates into variability in efficacy
An analysis of pooled data from these three Phase II studies found significant associations between axitinib
exposure and efficacy outcomes [31]. In this population PK analysis (n = 178) assessing data from 168 patients
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Figure 3. Design of the Phase II 1046 study, baseline axitinib exposure levels and objective response rate by study group .
†For at least two consecutive weeks.
‡Ten patients withdrew during the lead-in period.
§Subset of 73 patients with serial 6-h pharmacokinetic sampling, mean AUC24 prior to randomization.
AUC24: Area under the plasma concentration–time curve from 0 to 24 h; b.i.d.: Twice-daily; BP: Blood pressure; CI: Confidence interval;
HTN: Hypertension; ORR: Objective response rate.
with mRCC for whom data were available, the median (range) axitinib exposure at the end of 4 weeks of study
treatment at 5 mg b.i.d. was 375 ng·h/ml (32.8–1728 ng·h/ml) [31]. Logistic regression analysis found a significant
relationship between axitinib exposure and the probability of response (Response Evaluation Criteria in Solid
Tumors [RECIST]-based objective responses [OR]) in these patients (p < 0.0001); this translated into a 1.5-fold
increase in the probability of achieving a partial response for every 100 ng·h/ml increase in AUC (Pfizer Ltd, Walton
Oaks, Surrey, UK, data on file) [31]. Data from this analysis were also used to explore the relationship between
AUC and the time-to-event endpoints of progression-free survival (PFS) and overall survival (OS). Univariate
Cox proportional regression analysis was performed using exposure (as measured by AUC) as both a categorical
and continuous variable; patients were stratified by AUC ≥300 ng·h/ml (high AUC) or <300 ng·h/ml (low
AUC) [31]. The 300 ng·h/ml cut-off used in the analysis was determined based on data from Liu et al. [32] (total
daily AUC, which correlated with the maximum reduction in blood flow and permeability, was determined to
be reached at ∼300 ng·h/ml). Median PFS and OS were significantly longer in the high-AUC group versus the
low-AUC group (13.8 vs 7.4 months [p = 0.003] and 37.4 vs 15.8 months [p < 0.001], respectively). When
AUC was assessed as a continuous variable (any value between the minimum value and maximum value), the
result was more significant than when using the 300 ng·h/ml cut-off; for PFS and OS, the hazard ratio [HR] was
0.871 (p = 0.001) and 0.810 (p < 0.001), respectively, for every 100 ng·h/ml increase in AUC [31]. These results
demonstrate significant associations between exposure and clinical response for axitinib (i.e., patients with lower
exposure are likely to receive less benefit than patients with higher exposure). Furthermore, as shown in Figure 2F,
even after dose optimization, patients who achieve a higher axitinib exposure seem to have a better clinical outcome;
these positive associations were further confirmed using data from the Phase II 1046 study [8]. Treatment-naı¨ve
patients with mRCC received axitinib 5 mg b.i.d. (Figure 3 [8,9]). At the end of a 4-week lead-in period, patients
with no >Grade 2 treatment-related adverse events (AEs), no dose reduction, blood pressure (BP) ≤150/90 mmHg
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and ≤2 antihypertensive drugs, for two consecutive weeks were randomly assigned (1:1) to either axitinib (Arm
A) or placebo (Arm B) dose escalation. Patients who did not meet the aforementioned criteria and were therefore
deemed not to require dose escalation continued at ≤5 mg b.i.d. (Arm C). It is worth noting that, using these
criteria, approximately half of all patients included in the study were identified as potential candidates for dose
escalation. The primary objective was to compare the proportion of patients achieving an OR between randomized
groups. Axitinib dose escalation significantly improved drug exposure and, as a consequence, objective response rate
(ORR), compared with placebo dose escalation: 30 patients (54%; 95% confidence interval [CI]: 40–67) versus
19 patients (34%; 95% CI: 22–48) in the axitinib and placebo dose-escalation groups, respectively, achieved an OR
(risk ratio: 1.58 [95% CI: 1.02–2.45]; one-sided; p = 0.019) [9]. In the nonrandomized group, 54 (59%; 95% CI:
49–70) patients had an OR, suggesting that patient selection criteria based on tolerability correctly indicated which
patients had adequate axitinib exposure levels at 5 mg b.i.d. or below, and therefore did not require dose escalation.
Decreasing tumor mass is not only a sign of efficacy but may bring clinical benefit in terms of symptom relief
(e.g., pain caused by metastases or paraneoplastic syndromes such as hypercalcemia). The HR for PFS, a secondary
endpoint in this trial, favored the axitinib dose-escalation group versus the placebo dose-escalation group (HR:
0.85; 95% CI: 0.54–1.35) but was not statistically significant (one-sided; p = 0.24) [8,9]. OS data, which were
not available at the time of the original analysis, demonstrated that the corresponding increase in drug exposure
in axitinib-escalated patients also translated into a trend toward improvement in OS compared with patients who
were eligible for dose escalation but who were placebo escalated (median OS was 42.7 months [95% CI: 24.7–not
estimable] for axitinib escalation vs 30.4 months [95% CI: 23.7–45.0] for placebo escalation); the improvement
in this secondary endpoint did not reach statistical significance (HR: 0.79; 95% CI: 0.49–1.27) [33]. Both the PFS
and OS secondary endpoints had limited power to reach statistical significance in this Phase II trial [9,33].
How can we address interpatient variability?
As has been described, there is interpatient variability in drug exposure with axitinib and increasing the dose, where
tolerated, leads to an increase in exposure. Although there is a broad correlation between axitinib exposure and
clinical benefit, there is no universal threshold above which response is guaranteed, reinforcing the importance of
adjusting the dose (and therefore the exposure) to find an optimal balance between efficacy and tolerability. To
address this, alternatives to fixed-dosing regimens have been explored; however, as outlined below, many of these
methods are not currently feasible for axitinib.
Therapeutic drug monitoring
Therapeutic drug monitoring is a technique whereby plasma drug concentrations are measured to individualize the
dose given to a patient and achieve a target blood concentration; it is a technique used with some anticonvulsants and
antibiotics (e.g., gentamicin) [21,34]. Given the expected variations among axitinib-treated patients, and the absence
of a universal ‘active’ target exposure level, scheduled PK measurements (e.g., maximum plasma concentration
and AUC) in individual patients for the purpose of guiding axitinib dosing are not performed in routine clinical
practice. Furthermore, the properties of the drug itself mean there are inherent difficulties when measuring plasma
concentrations; owing to the short half-life, axitinib concentrations rise and fall significantly during a dosing interval
and there is minimal accumulation at steady state [13] (i.e., a concentration level that is therapeutically effective
as long as regular doses are administered). In addition, axitinib degrades in the presence of light [35]; this could
result in artefactual readings and the physician prescribing an incorrectly high dose of axitinib to the patient with
resulting safety implications. With these limitations in mind, however, PK measurements could be considered on
an individual basis, and only after checking the patient’s level of compliance with treatment.
Phenotype-/genotype-guided dosing
Phenotype-guided dosing is based on the ability of an individual to process a drug according to phenotype
(i.e., an individual’s enzymatic capability). For example, the midazolam clearance test assesses CYP3A activity and
midazolam has been shown to be a good predictor of exposure to other CYP3A4 substrates, such as gefitinib [36].
Genotype-guided dosing is based on an individual’s genetic make-up and single nucleotide polymorphisms within
their drug disposition genes (e.g., genes encoding for drug-metabolizing enzymes, efflux transporters and drug
targets) [21]. Genetic variation in the therapeutic target may also define variability in efficacy. There are currently no
validated genetic biomarkers available to guide dosing in axitinib patients; in a meta-analysis using pooled data from
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11 healthy volunteer clinical pharmacology trials, no polymorphisms in a number of drug-metabolizing enzymes
or transporters were found to be predictors of axitinib PK variability [37].
Toxicity-adjusted dosing
Toxicity-adjusted dosing is based on the theory that specific toxicities are dependent, at least in part, on drug
exposure. AEs can therefore be used to guide dosing and to achieve maximum tolerated drug levels for each
individual patient. This method of dose adaptation is already readily used to decrease the dose of axitinib when
intolerable AEs arise but can also be used to inform decisions to increase the dose when they do not. Of these
AEs, hypertension has been validated as a clinical parameter that can be used to identify patients eligible for dose
escalation, and there is significant evidence that patients who develop hypertension with anti-VEGFR therapies
may have better clinical outcomes. In a population PK pooled analysis, logistic regression was performed (using data
from patients with mRCC) to evaluate the relationship between RECIST-based ORs and diastolic blood pressure
(dBP) [31]. Results demonstrated a strong association (p = 0.0042) between change in dBP and the probability of
a response (i.e., 1.6-fold increase in the probability of achieving a partial response for every 10 mmHg increase
in dBP; Pfizer Ltd, data on file) [31]. A univariate Cox proportional regression was then performed to explore
the relationship between dBP and PFS or OS, using dBP as both a categorical and continuous variable. Median
PFS was 14.6 months in patients with dBP ≥90 mmHg versus 7.86 months in patients with dBP <90 mmHg
(HR: 0.590; p = 0.006) [31]. Similarly, the median OS was longer in patients with dBP ≥90 mmHg than in
patients with dBP <90 mmHg (29.5 vs 18.5 months; HR: 0.622; p = 0.024) [31]. Although these results are
notable, they do not indicate that the absence of hypertension means a patient is not gaining benefit from the
drug; indeed, these findings may be another element of interpatient variability. Also, the intent is not to keep the
patient in a hypertensive state; once a patient on any anti-VEGFR agent develops an increase in BP, the patient
needs to be treated with standard antihypertensive therapy to manage this condition. Therefore, increases in BP
during treatment with axitinib may serve as a biomarker for effective drug dosing but should be considered as one
parameter of the overall AE assessment and managed accordingly. At present, BP and AEs serve as the only points
by which to guide axitinib dosing. However, more individualized approaches to dose titration are currently being
explored (see ‘Individualizing the axitinib dose – practical guidance’ section).
Axitinib dose individualization in clinical practice
The favorable benefit–risk ratio supports individualized dosing
When dosed appropriately, axitinib has a favorable benefit–risk profile; it is a highly potent and selective drug
that has a manageable side-effect profile (i.e., potency and selectivity are not achieved at the expense of increased
toxicity) and provides meaningful clinical benefit in patients who have progressed on a previous TKI [10].
Axitinib has several distinguishing properties that help to explain its AE profile and to differentiate it from other
VEGFR inhibitors. For example, axitinib is a more potent inhibitor of VEGFR-1, -2 and -3 than other approved
VEGFR TKIs, with the exception of cabozantinib for VEGFR-2 [38–41]. Potent VEGFR inhibition may improve
effectiveness and ease of dose adjustment [38], but does not mean that safety is compromised. Axitinib is also a
selective inhibitor of VEGFR-1, -2 and -3 at subnanomolar concentrations in vitro [38,39]; its IC50 (the half maximal
inhibitory concentration) is tenfold lower for VEGFRs than for other receptors tested [39]. This high selectivity of
axitinib for the VEGFRs over other receptor tyrosine kinases means that there are reduced ‘off-target’ effects that
may lead to additional toxicities [42].
With regard to efficacy, in a large, multicenter Phase III study (AXIS) of 723 patients with mRCC [10,13],
axitinib significantly improved PFS in the second line compared with sorafenib: median PFS was 6.8 months
(95% CI: 6.4–8.3) for axitinib versus 4.7 months (95% CI: 4.6–6.3) for sorafenib (HR: 0.67; 95% CI: 0.56–0.81;
p < 0.0001; Figure 4) [10,13]. Patients in the AXIS trial who met clinical criteria (i.e., if, after two consecutive
weeks, no AEs >Grade 2 and BP ≤150/90 mmHg and no antihypertension treatment) were encouraged to have
their dose escalated [10].
The tolerability of axitinib has been shown to be similar to that of sorafenib, with some differences. Common
axitinib-associated AEs, such as diarrhea, hypertension and fatigue, have been reported with other VEGFR in-
hibitors [10]. Other AEs less commonly reported with axitinib were hand–foot syndrome, cutaneous toxicities and
myelosuppression, highlighting one potential advantage of a more specific VEGFR inhibitor [10]. The manageable
AE profile in second-line use also allows the flexibility to increase the dose in patients who can tolerate it. Overall,
the side-effect profile of axitinib may be more tolerable for some patients and may allow them to remain on therapy
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Figure 4. Kaplan–Meier curve of progression-free survival of axitinib versus sorafenib by independent assessment
for the overall population in a Phase III trial involving patients with relapsed/refractory advanced renal cell
carcinoma.
CI: Confidence interval; HR: Hazard ratio; mPFS, Median progression-free survival; PFS: Progression-free survival.
for longer while maintaining clinical benefit [10]. Indeed, data from a pooled analysis of axitinib patients showed
declining or stable rates of most AEs over time, supporting acceptable long-term safety [43]. Furthermore, in a
post hoc analysis of data from the AXIS trial [44], the toxicity profile was similar regardless of the duration of prior
sunitinib (i.e., there is no evidence of additive toxicity with use of second-line axitinib with a longer vs shorter
duration of first-line TKI use).
Individualizing the axitinib dose – practical guidance
Learnings about interpatient variability and knowledge of other TKIs led to awareness of the need to account for
interpatient variability when dosing axitinib. The favorable AE profile of axitinib allows for dose escalation, and
the option to dose escalate (based on clinical criteria) was introduced into Phase II and III clinical trials [9,10]. In
the AXIS trial [10], approximately the same proportion of patients remained on 5 mg b.i.d., were dose escalated to
>5 mg b.i.d. and were dose reduced to <5 mg b.i.d. [45], illustrating that three broader groups of patients exist:
those who can tolerate and may benefit from a dose escalation >5 mg b.i.d.; those who have manageable toxicity
at 5 mg b.i.d. but are not suitable for a dose escalation; and those who require a dose reduction to <5 mg b.i.d.
It is not possible to predict which of these three groups a patient will fall into before starting axitinib therapy, and
physicians should not prejudge the patient sitting in front of them. To help guide physicians (and explain this
concept to patients so they are aware of the possibility that their initial dose may be modified), a schematic depicting
the proposed dose adjustment process may be helpful (Figure 5). This depicts an initial 2–4-week initiation period
at 5 mg b.i.d. to assess tolerability. This is followed by a dosing checkpoint at which the physician decides which of
the three broader groups a patient fits into so that they can act accordingly (i.e., to keep the patient on 5 mg b.i.d.
or to increase/decrease the dose). Further dosing checkpoints should be made at 2–4-week intervals until a steady,
tolerated dose is achieved for that individual patient. It is important that the dosing checkpoint is used to assess the
correct dose and that dose adjustments are made if required; physicians should not wait until the 3-month CT scan
to modify the dose because they risk compromising outcomes for their patients. Guidance regarding the clinical
criteria and how to escalate or reduce the dose of axitinib is outlined in Figure 6 [13]. If the patient is experiencing
unmanageable AEs, the dose will need to be reduced; however, a dose reduction does not preclude a subsequent
re-escalation once AEs have resolved, if appropriate. For some patients, taking a short break (e.g., 2–3 days) before
restarting at the reduced dose may help initial toxicities to resolve quickly; the short half-life of axitinib does mean
that toxicities usually resolve rapidly after treatment interruption [13,46]. Dose interruption to allow resolution prior
to considering dose reduction may be particularly helpful for severe or unmanageable toxicities. Dose interruptions
(owing to missed dose or toxicity) were reported in >75% of all treated patients (axitinib or sorafenib) in the AXIS
trial [10]. If the patient receives axitinib 10 mg b.i.d. without experiencing elevated BP or other dose-related AEs,
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Starting dose:
5 mg b.i.d.
2–4-week
initiation phase
Incorrect dosing
• Starting dose ≠ 5 mg b.i.d.
• Once-daily dosing
Dose optimization/
confirmation phase
Continued
treatment
Initial dosing
checkpoint
Frequent BP monitoring
Regular dose reassessment
3-month CT
scan
Figure 5. Individualizing the dose for every patient.
b.i.d.: Twice-daily; BP: Blood pressure.
Regular assessment (and reassessment) for dose escalation should occur;
dose escalation may be considered at any point during axitinib
treatment (if below criteria are met)
Escalation, if, after two consecutive weeks:
no AEs >Grade 2 and BP ≤150/90 mmHg
and no anti-HTN treatment†
Starting dose:
5 mg b.i.d.
Increase dose:
7 mg b.i.d.
Increase dose:
10 mg b.i.d.
Decrease dose:
2 mg b.i.d.
Decrease dose:
3 mg b.i.d.
Starting dose:
5 mg b.i.d.
AEs requiring dose reduction,
despite proactive therapy management
Figure 6. Clinical criteria for axitinib dose adjustment. (A) Criteria for increasing or (B) decreasing the axitinib dose,
dependent on individual safety and tolerability (according to the label).
†Dose escalation is currently not recommended if a patient is already hypertensive/taking antihypertensive
medication according to the axitinib summary of product characteristics [13], but frequently occurs (with appropriate
monitoring and treatment) in real-world clinical practice.
AE: Adverse event; b.i.d.: Twice-daily; BP: Blood pressure; HTN: Hypertension.
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treatment should be maintained at this dose; escalating the dose beyond 10 mg b.i.d. should be avoided because of
a lack of supportive data [13].
Alternative schema may highlight other methods to optimize axitinib dose but require further study [47,48]. Most
recently, as part of an ongoing Phase II trial of axitinib for mRCC after PD-1/PD-L1 inhibition (www.clinicaltrials.
gov, NCT02579811), patients receive axitinib 5 mg b.i.d. with the dose increased in 1 mg b.i.d. increments every
14 days if no Grade 2 axitinib-related AEs are observed. Rather than immediately reducing the dose for Grade 2
AEs, patients will undergo a brief treatment break and resume with the same dose if AE severity falls below Grade
2. Doses will be reduced (in 1 mg b.i.d. increments) in patients with recurrent Grade 2 AEs despite treatment
break, and per physician discretion. In this way the dose intensity of axitinib can be maximized while AEs are kept
at a manageable level.
Proactive management of AEs
Although some patients will require a dose reduction because of AEs, it is important that AEs are, in the first instance,
managed proactively [46]. During axitinib treatment, patients should be closely monitored for the development of
AEs, which should be treated promptly and in line with standard medical interventions [39,49–50]. The physician’s
role is to provide maximum benefit from axitinib by proactively managing both the dose and any toxicities that may
arise. Although toxicity may increase with increased dose, safety concerns should not prohibit dose escalation in
patients who meet the clinical eligibility criteria. In the AXIS study, treatment-related AEs and Grade ≥3 treatment-
related AEs in the axitinib arm were similar in dose-escalated (90.2 and 50.0%, respectively) and non-escalated
(90.7 and 48.9%, respectively) patients [51]. Patients should also be educated about the potential occurrence of side
effects and how to recognize and manage them as soon as they arise [46], particularly in the case of common AEs such
as diarrhea, fatigue/asthenia, dysphonia and hypertension. For example, diarrhea can be managed through dietary
modifications and concomitant antidiarrheal medication, fatigue/asthenia managed through energy-conserving
strategies and dysphonia through ample water intake and avoidance of irritants such as tobacco smoke [46]. It
is important that BP is under control before treatment initiation and is frequently monitored during axitinib
treatment, and that the importance of hypertension is clearly communicated to patients.
Appropriate management of hypertension, if it arises, is essential. If antihypertensive agents are required to
control high BP, treatment guidance (e.g., European Society of Cardiology guidelines) [52] should be followed.
However, angiotensin system inhibitors may now be the treatment of choice, following analyses of data from
Izzedine et al. [53] and McKay et al. [54] showing that concomitant use of angiotensin system inhibitors is associated
with significant improvements in survival outcomes in patients with mRCC. Dose escalation is currently not
recommended if a patient is already hypertensive/taking antihypertensive medication according to the axitinib
summary of product characteristics [13], but frequently occurs (with appropriate monitoring and treatment) in
real-world clinical practice.
Conclusion
Compared with other approved VEGFR TKIs, axitinib is a highly potent and selective VEGFR inhibitor; it is
these properties that contribute to the effectiveness of axitinib without compromising its safety profile. However,
achieving maximum benefit from axitinib may be hindered in certain patients by inappropriate individual dosing.
There are a number of factors that may contribute to this, including incorrect once-daily dosing (the short half-life
of axitinib means that therapeutic levels are only maintained by b.i.d. dosing) or initiating treatment below the
appropriate starting dose of axitinib of 5 mg b.i.d. Once a patient has been initiated on the 5 mg b.i.d. starting
dose, further dose modifications may be required because this nonindividualized fixed dose of axitinib does not
take into account interpatient variability, which has been demonstrated not only for axitinib but for all oral mRCC
drugs. Clinical studies have shown that after initiation of axitinib at 5 mg b.i.d., three broader groups of patients
exist: those who can tolerate and may benefit from a dose escalation >5 mg b.i.d.; those who have manageable
toxicity at 5 mg b.i.d. but are not suitable for a dose escalation; and those who require a dose reduction to <5 mg
b.i.d. Therefore, it is important to use clinical criteria to assess which group a patient falls into and to follow practical
guidance regarding individualized treatment. By following this guidance, physicians can reach the full potential of
axitinib and optimize outcomes for their patients, without compromising safety. Proactive management of AEs is
a key part of overall therapy management with any oncology drug, and educating patients on what toxicities may
occur is part of this process. If toxicities do arise, the short half-life of axitinib usually allows them to resolve rapidly
after a short break in treatment.
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Future perspective
New agents have recently been approved for the management of patients who have previously failed to respond
to first-line TKIs. Nivolumab, a checkpoint inhibitor that restores T-cell function, has demonstrated statistically
significant and clinically meaningful OS and ORR benefit when compared with everolimus [55]. Cabozantinib, a
new generation oral TKI that targets MET, AXL and VEGFR, has also shown a statistically significant benefit in
three efficacy endpoints (ORR, PFS and OS) versus everolimus [56]. Both agents have enriched the armamentarium
for renal cell carcinoma treatment in second-line.
In the future, axitinib may come to play a major role in first-line. Based on a synergism between checkpoint
inhibitors with some TKIs, the concept of combining these two strategies was investigated in Phase I trials. The
combination of a potent and selective VEGFR inhibitor (such as axitinib) with a checkpoint inhibitor (avelumab
or pembrolizumab) proved to be feasible in terms of safety. Moreover, initial efficacy data were highly promising
with response rates up to 75% [57,58].
Executive summary
Rationale for individualized dosing
 Axitinib is a potent, selective, second-generation VEGFR inhibitor for the second-line treatment of metastatic
renal cell carcinoma.
 Individualized dosing, accounting for interpatient variability, is the preferred approach to optimize efficacy,
while minimizing adverse effects.
How the dosing schedule & starting dose of axitinib were determined
 Axitinib has a half-life of 2.5–6.1 h and reaches a steady state within 2–3 days of the initial dose, maintained by
twice-daily (b.i.d.) dosing.
 The recommended dose of axitinib is 5 mg b.i.d., as confirmed in AXIS.
Interpatient variability in axitinib exposure
 Various factors, including the absorption, distribution, metabolism, elimination, drug–drug interactions, genetic
variations and patient compliance, all affect drug exposure and contribute to interpatient variability.
 Pharmacokinetic data confirm that dose escalation increases drug exposure in patients who are able to tolerate it.
Interpatient variability in drug exposure translates into variability in efficacy
 Clinical trials have demonstrated significant associations between axitinib exposure and efficacy outcomes,
leading to a 1.5-fold increase in the probability of achieving a partial response for every 100 ng·h/ml increase in
area under the concentration–time curve (AUC).
 In patients with AUC ≥300 ng·h/ml, median progression-free survival and overall survival were found to be
significantly longer compared with those with AUC <300 ng·h/ml, and results were even more significant when
AUC was assessed as a continuous variable.
 Dose escalation of axitinib also resulted in a significant improvement in drug exposure, with a positive trend
toward improvement in overall survival.
How can we address interpatient variability?
 Therapeutic drug monitoring and phenotype-/genotype-guided dosing are two methods that can be used to
address interpatient variability but are currently not feasible for use with axitinib.
 Toxicity-adjusted dosing can be used for axitinib based on adverse events, of which hypertension has been
validated as a clinical parameter to identify patients eligible for dose escalation.
Axitinib dose individualization in clinical practice
 Axitinib has been shown to have a favorable benefit–risk profile due to its high selectivity and potency with good
tolerability, supporting individualized dosing.
 Axitinib is recommended to be initiated at 5 mg b.i.d. for 2–4 weeks, followed by a dosing checkpoint to identify
the need for dose adjustment, with further dosing checkpoints every 2–4 weeks until a steady, tolerated dose is
achieved.
 Adverse effects should be managed proactively, according to treatment guidance, and patients should be
educated regarding possible toxicities that could arise.
Conclusion
 Axitinib is a highly potent and selective VEGFR inhibitor, which contributes to its effectiveness and good safety
profile.
 Interpatient variability should be taken into account to optimize clinical outcomes without compromising safety,
based on clinical criteria to identify patients that would benefit from dose escalation, reduction or those that are
not suitable for dose escalation.
 Proactive management of adverse events and appropriate patient education are also essential elements of
therapeutic management.
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Based on these findings, the combination of axitinib and avelumab is being explored in a randomized Phase III
trial versus sunitinib (JAVELIN RENAL 101; NCT02684006), as well as in combination with pembrolizumab
(KEYNOTE-426; NCT02853331). In this context, the dosing flexibility of axitinib may be valuable in exploiting
the synergy of the combination, since lower doses of anti-angiogenic agents may be more effective than conventional
doses and also positively impact the efficacy/safety ratio [59].
Supplementary data
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